ADRB1 and cardiovascular disorder: Due to the lack of intrinsic activity, β1-AR blockers prevent the signal transduction of β1-AR when bound to the ligand, decreasing the response of the heart to sympathetic stimulation, which in turn leads to the therapeutic effects in cardiovascular diseases.